Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,490.83 -10.82 -0.07%
S&P 500 1,877.76 2.37 0.13%
NASDAQ 4,142.74 15.77 0.38%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results



 Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012
                              Financial Results

Investor Conference Call to be held Thursday, November 8, 2012 at 8:30am EST

PR Newswire

NEW YORK, Nov. 6, 2012

NEW YORK, Nov. 6, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:
KERX), a biopharmaceutical company focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease, today announced that a conference call will be
held on Thursday, November 8, 2012 at 8:30 a.m. EST to discuss results for the
third quarter ended September 30, 2012 and a business outlook for the
remainder of 2012. Ron Bentsur, Chief Executive Officer of Keryx, will host
the call.

In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio
recording of the conference call will be available for replay at
http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release
to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for
the treatment of hyperphosphatemia (elevated phosphate levels) in patients
with end-stage renal disease is being conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2
development for the management of phosphorus and iron deficiency in anemic
patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. 
Keryx is headquartered in New York City. 

KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Website: http://www.keryx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement